ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ORPH Open Orphan Plc

10.00
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 10.00 9.50 10.50 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Open Orphan Share Discussion Threads

Showing 28676 to 28694 of 30350 messages
Chat Pages: Latest  1154  1153  1152  1151  1150  1149  1148  1147  1146  1145  1144  1143  Older
DateSubjectAuthorDiscuss
30/6/2022
07:50
They wouldn't take on anything without being well paid to do it, CF is a hard businessman when it comes down to it.
troutisout
30/6/2022
07:48
Another very positive RNS this morning re-affirming hVivo (and ORPH) emerging importance in the sector.

Just one (probably naiive) question that has occurred to me (and I do fear the sikhs could jump all over it):

In the short/medium term is this revenue earning for ORPH or is this an ORPH investment of resources (with consequent expensing/short term operating profitability considerations) which will lead to longer term revenue receipts?

lfdkmp
30/6/2022
07:42
Some liquidity for the sellers I suppose lol
jason_scrap
30/6/2022
07:40
Today's news = Lol
jason_scrap
30/6/2022
07:32
I think m5 you are falling into the traders trap, they will keep posting about Mo buying shares and the same with JS over at POLB, if it happens they will sell into any positive spike and then go on and on about there being no new deveoplments for weeks as the Director has bought, seen this so many times.......
troutisout
30/6/2022
07:32
Very nice. A long way to go until the actual omicron challenge study, but good to see the model development contracted.
1gw
30/6/2022
07:31
There will come a point when a large pharma company decides that removing little old ORPHs services from other companies will benefit them and this will be gone.
mikeh30
30/6/2022
07:27
GOOD MORNING.........
troutisout
29/6/2022
19:21
4132 filtered
666james
29/6/2022
16:43
Hello 250k at 12p.
m5
29/6/2022
11:23
MO needs to buy some shares as soon as he is able to . He did say he would so for him to not to do so would not be a good sign imo.
jeanesy
29/6/2022
11:06
Cheers marvelman.

Curious that there wasn't an "Exercise of Options" RNS this morning if Maurice Treacy's options did expire yesterday. Although the 2021 annual report said that the "contractual life" of these options was 0.5 years (implying expiry at end June, or more probably 28th June given originally granted on 28th June 2019), the 2020 annual report quoted a contractual life of 3.5 years (implying expiry end-June 2024) and the 2019 annual report quoted a contractual life of 5 years (implying expiry end-2024).

Perhaps a question for IR if we don't get an "Exercise of Options" RNS by 1st July.

1gw
29/6/2022
09:29
troutisout 29 Jun '22 - 08:58 - 4124 of 4125

From these levels I would like him to buy, if he can. Hopefully you are right and we have more news on the way, but then look at where we are share price wise. As our new CEO I would like him to have skin in the game. We wait and see.

m5
29/6/2022
09:00
From THE TIMES -

GSK invests £1bn to fight neglected tropical diseases.
One of Britain’s biggest drugs companies is to invest £1 billion over the next decade in researching new medicines and vaccines to tackle infectious diseases that hit poorer countries.

GSK, listed in London, said yesterday it would focus on malaria, tuberculosis and HIV, as well as the 20 tropical diseases that traditionally receive limited research funding. These neglected tropical diseases, or NTDs, which include leprosy, dengue, rabies and scabies, affect more than 1.7 billion people.

The FTSE 100 group, which is based in West London and employs about 94,000 people, will also look at resistance to antibiotics.

The announcement was made at a conference yesterday on Malaria and Neglected Tropical Diseases in Rwanda’s capital city, Kigali, bringing together world leaders, businesses and academics to discuss how to tackle these illnesses. According to the World Health Organisation, by 2030 one hundred countries should have eliminated at least one NTD.

qackers
29/6/2022
08:58
Why? It would mean there would be nothing else short term to look forward to, when he can't buy there is likely to be more material inside information that precludes him from buying the shares. It's this information that is going to take the Company forward, not whether he owns some shares or not.
troutisout
28/6/2022
18:27
Said before, this was pumped/dumped by the gang with their multiple ids...
sikhthetech
28/6/2022
15:00
The Orphan Army's dead bodies are strewn all over the AIM Exchange.
They got bad intelligence from our Mr.Friel.

chica1
28/6/2022
14:04
Down to new year lows now :(
jeanesy
28/6/2022
12:14
Market going up....ORPH going down. The wisdom of crowds.
bonagratia
Chat Pages: Latest  1154  1153  1152  1151  1150  1149  1148  1147  1146  1145  1144  1143  Older

Your Recent History

Delayed Upgrade Clock